Webinar

Demystifying HbA1c testing at the point of care and the impacts of COVID-19 on patients with diabetes

Today, many medical providers are hesitant to adopt a point-of-care testing (POCT) model for chronic disease management. During this webinar, our esteemed panel will discuss, in general, the differences between central lab and POCT, before moving the conversation into specifics about the benefits of testing for HbA1c at a point-of-care facility. In addition, our speakers will discuss the stringent quality standards in place for HbA1c POCT and the impact that a simplified user interface of these instruments can have on both the operator and patient experience. What a COVID-19 diagnosis means for a patient with diabetes and what potential health impacts could follow will also be discussed.

Following this webinar, you will be able to:

  • List the key benefits of HbA1c point-of-care testing.
  • Identify the quality measures HbA1c instruments must adhere to throughout the product lifecycle.
  • Identify possible long-term health implications of COVID-19 on those living with Diabetes.

CE credits & certificate of attendance

SelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. Attendees of this webinar are entitled to ACCENT credits from the AACC.

Speakers

Cameron Smith-Craig
Cameron Smith-Craig
Associate Editor, SelectScience
Erna Lenters Westra
Erna Lenters Westra
Department of Clinical Chemistry, The Netherlands. European Reference Laboratory for Glycohemoglobin, The Netherlands
Garry John
Garry John
Norfolk and Norwich University Hospital, Norwich, UK. Secretary IFCC Scientific Division Executive Committee
Emma English
Emma English
School of Health Sciences, Faculty of Medicine and Health, University of East Anglia, Norwich, Norfolk, UK

Links